Gene Name	Entrez ID	Drug Name	Chembl ID	Interaction Types	Sources	publications
C6	729	CARBENOXOLONE	CHEMBL499915	inhibitor	GuideToPharmacologyInteractions
C6	729	FLUFENAMIC ACID	CHEMBL23588	inhibitor	GuideToPharmacologyInteractions
C6	729	OCTANOL	CHEMBL26215	inhibitor	GuideToPharmacologyInteractions
C6	729	cA2	CHEMBL2109588	inhibitor	GuideToPharmacologyInteractions

Gene Name	Variant	Alleles	Chemical	Phenotype Category	Significance	Notes	Sentence	Publications	Annotation ID
C6	rs9200	CC + CT	tacrolimus	metabolism/PK	no	When considering DONOR genotype - no significant difference in concentration/dose ratio was seen between those with the CC or CT genotype and to those with the TT genotype at weeks 1-4 of treatment. Patients with hepatocellular carcinoma. Please note that alleles have been complemented to the plus chromosomal strand.	Genotypes CC + CT are not associated with dose-adjusted trough concentrations of tacrolimus in people with liver transplantation as compared to genotype TT.	28685716	1448820481
C6	rs9200	CC + CT	tacrolimus	metabolism/PK	yes	When considering RECIPIENT genotype - those with the CC or CT genotype had decreased concentration/dose ratios as compared to those with the TT genotype at weeks 1, 2 and 3 of treatment. No significant difference was seen at week 4. In multiple linear regression analysis, recipient rs9200 genotype was associated with concentration/dose ratio at week 1 (p=0.005), 2 (p=0.045) and 3 (p=0.033) of treatment. Patients with hepatocellular carcinoma. Please note that alleles have been complemented to the plus chromosomal strand.	Genotypes CC + CT are associated with decreased dose-adjusted trough concentrations of tacrolimus in people with liver transplantation as compared to genotype TT.	28685716	1448820472
C6	rs10052999	CT	tacrolimus	metabolism/PK	no	When considering RECIPIENT genotype - no significant difference in concentration/dose ratio was seen between those with the CT genotype and those with the CC or TT genotypes at weeks 1-4 of treatment. Patients with hepatocellular carcinoma.	Genotype CT is not associated with dose-adjusted trough concentrations of tacrolimus in people with liver transplantation as compared to genotypes CC + TT.	28685716	1448820497
C6	rs10052999	CC + TT	tacrolimus	metabolism/PK	yes	When considering DONOR genotype - those with the CC or TT genotype had decreased concentration/dose ratios as compared to those with the CT genotype at weeks 2-4 of treatment. No significant difference was seen at week 1. In multiple linear regression analysis, donor rs10052999 genotype was significantly associated with concentration/dose ratio at week 4 (p=0.001) of treatment. Patients with hepatocellular carcinoma.	Genotypes CC + TT are associated with decreased dose-adjusted trough concentrations of tacrolimus in people with liver transplantation as compared to genotype CT.	28685716	1448820506
C6	rs3805715	AA	tacrolimus	metabolism/PK	no	No significant difference was seen when considering RECIPIENT genotype at week 4 of treatment. Patients with hepatocellular carcinoma.	Genotype AA is not associated with dose-adjusted trough concentrations of tacrolimus in people with liver transplantation as compared to genotypes AG + GG.	28685716	1448820555
C6	rs3805716	AA	tacrolimus	metabolism/PK	no	No significant difference was seen when considering DONOR genotype at week 4 of treatment. Patients with hepatocellular carcinoma.	Genotype AA is not associated with dose-adjusted trough concentrations of tacrolimus in people with liver transplantation as compared to genotypes AT + TT.	28685716	1448820562
C6	rs6865420	AC	tacrolimus	metabolism/PK	no	No significant difference was seen when considering DONOR genotype at week 3 of treatment. Patients with hepatocellular carcinoma.	Genotype AC is not associated with dose-adjusted trough concentrations of tacrolimus in people with liver transplantation as compared to genotypes AA + CC.	28685716	1448820570
C6	rs7443562	AA	tacrolimus	metabolism/PK	no	No significant difference was seen when considering DONOR genotype at week 2 of treatment. Patients with hepatocellular carcinoma.	Genotype AA is not associated with dose-adjusted trough concentrations of tacrolimus in people with liver transplantation as compared to genotypes AG + GG.	28685716	1448820578